

**PHARMANUTRA S.P.A.****LOSS OF SME STATUS**

Pisa, 8 January 2024 – [PharmaNutra S.p.A.](https://www.pharmanutra.it) (MTA; Ticker PHN), a company specialising in the sector of mineral-based nutritional supplements and medical devices for muscles and joints, pursuant to Article 2-ter, paragraph 2, of the Consob Regulations no. 11971/1999 (“**Issuers' Regulations**”), announces that, having exceeded the market capitalization threshold of 500 million euros for three consecutive years, as of 1 January 2024 it no longer qualifies as a “Small and Medium Enterprise” (“**SME**”) pursuant to Article 1, paragraph 1, letter w-quater.1, of Legislative Decree no. 58/1998 (“**TUF**”).

It should be noted that, as a result of the loss of SME status, the first relevant threshold for the purposes of disclosure requirements for significant shareholdings is set at 3% of capital, pursuant to Article 120, paragraph 2, of the TUF.

Therefore, shareholders who, as of the date of publication of this press release, hold an interest of more than 3% and less than 5%, must notify Consob and PharmaNutra, within fifteen trading days of the aforesaid date, in accordance with Articles 117, paragraph 2-bis, and 121, paragraph 3-bis, of the Issuers' Regulations.

**PharmaNutra S.p.A.**

*Founded and led by the President Andrea Lacorte and Vice President Roberto Lacorte, PharmaNutra was established in 2003. It develops unique nutritional supplements and innovative nutritional devices, handling the entire production process, from proprietary raw materials to finished product. PharmaNutra is a leader in the production of iron-based nutritional supplements with the SiderAL® brand, where it can claim important Sucrosomial® Technology patents, and is considered one of the top players in the sector of medical devices dedicated to the restoration of joint capacity thanks to the Cetilar® brand, now on the market also with Cetilar® Nutrition, a line of supplements designed for those who practice sport constantly. Over the years the Group - present abroad in 85 countries - has developed precise strategy for the management and production of intellectual property, founded on the integrated management of all the various elements: proprietary raw materials, patents, brands and clinical evidence.*

[PharmaNutra.it](https://www.pharmanutra.it)

For further information:

**PharmaNutra S.p.A.**

Via Delle Lenze, 216/b - 56122 Pisa  
Tel. +39 050 7846500  
[investorrelation@pharmanutra.it](mailto:investorrelation@pharmanutra.it)

Internal Press Office  
[press@calabughi.com](mailto:press@calabughi.com)

**Press Office - Spriano Communication & Partners**

Via Santa Radegonda, 16 - 20121 Milan  
Tel. +39 02 83635708

Matteo Russo  
[mrusso@sprianocommunication.com](mailto:mrusso@sprianocommunication.com)  
Cristina Tronconi  
[ctronconi@sprianocommunication.com](mailto:ctronconi@sprianocommunication.com)